热景生物(688068)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
暂无数据
  盈利预测
据热景生物三季报分析:

  盈利能力明显恶化,总资产收益能力急剧下降

  成长能力有所削弱,公司规模由扩张变为收缩

  偿债能力有所削弱,短期偿债能力很强

  运营能力明显恶化,总资产利用效率腰斩

  现金流能力明显恶化,现金满足投资能力被严重削弱

  财务数据
    截至第三季度实现净利润0.47亿元,每股收益0.61元。

    截至第三季度最新股东权益340362.47万元,未分配利润298650.37万元。

    截至第三季度最新总资产360426.33万元,负债20063.86万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入406,916,772.66307,007,061.27202,939,171.053,556,551,569.15
营业总成本401,559,759.11263,337,262.01150,641,590.422,297,525,641.45
营业利润45,775,598.5385,580,413.4568,617,202.231,090,853,295.1
利润总额45,149,357.6586,087,716.9369,257,895.561,075,220,675.86
净利润46,935,484.8576,396,016.6956,095,829.44925,116,988.04
其他综合收益-97,183.48-348,880.58-269,443.22
综合收益总额46,838,301.3776,047,136.1156,095,829.44925,386,431.26
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计931,272,157.321,195,302,584.611,354,547,109.621,798,268,654.72
非流动资产合计2,672,991,157.842,505,802,495.842,349,263,841.022,101,003,185.1
资产总计3,604,263,315.163,701,105,080.453,703,810,950.643,899,271,839.82
流动负债合计169,142,067.12239,761,895.96264,591,095.15511,306,546.3
非流动负债合计31,496,574.5730,852,435.2635,917,451.5734,282,577.47
负债合计200,638,641.69270,614,331.22300,508,546.72545,589,123.77
归属于母公司股东权益合计3,400,982,718.453,428,778,232.713,387,633,001.373,335,223,635.33
股东权益合计3,403,624,673.473,430,490,749.233,403,302,403.923,353,682,716.05
负债和股东权益合计3,604,263,315.163,701,105,080.453,703,810,950.643,899,271,839.82
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计437,535,320.83343,756,387.17163,459,229.153,395,105,604.4
经营活动现金流出小计788,880,801.82543,275,673.17406,243,576.752,416,352,436.47
经营活动产生的现金流量净额-351,345,480.99-199,519,286-242,784,347.6978,753,167.93
投资活动现金流入小计966,149,915.82815,601,272.57607,831,021.952,095,171,566.38
投资活动现金流出小计937,578,624.37803,516,351.36561,508,312.583,225,223,633.36
投资活动产生的现金流量净额28,571,291.4512,084,921.2146,322,709.37-1,130,052,066.98
筹资活动现金流入小计7,140,351.117,140,351.11-8,320,000
筹资活动现金流出小计16,444,443.6516,956,935.066,483,618.22493,307,022.35
筹资活动产生的现金流量净额-9,304,092.54-9,816,583.95-6,483,618.22-484,987,022.35
汇率变动对现金及现金等价物的影响2,965,935.75-366,537.32-1,285,097.965,198,170.06
现金及现金等价物净增加额-329,112,346.33-197,617,486.06-204,230,354.41-631,087,751.34
期末现金及现金等价物余额194,102,372.57325,597,232.84318,984,364.49523,214,718.9
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润0.47亿元,每股收益0.61元。

    截至第三季度最新股东权益340362.47万元,未分配利润298650.37万元。

    截至第三季度最新总资产360426.33万元,负债20063.86万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入406,916,772.66307,007,061.27202,939,171.053,556,551,569.15
营业总成本401,559,759.11263,337,262.01150,641,590.422,297,525,641.45
营业利润45,775,598.5385,580,413.4568,617,202.231,090,853,295.1
利润总额45,149,357.6586,087,716.9369,257,895.561,075,220,675.86
净利润46,935,484.8576,396,016.6956,095,829.44925,116,988.04
其他综合收益-97,183.48-348,880.58-269,443.22
综合收益总额46,838,301.3776,047,136.1156,095,829.44925,386,431.26
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计931,272,157.321,195,302,584.611,354,547,109.621,798,268,654.72
非流动资产合计2,672,991,157.842,505,802,495.842,349,263,841.022,101,003,185.1
资产总计3,604,263,315.163,701,105,080.453,703,810,950.643,899,271,839.82
流动负债合计169,142,067.12239,761,895.96264,591,095.15511,306,546.3
非流动负债合计31,496,574.5730,852,435.2635,917,451.5734,282,577.47
负债合计200,638,641.69270,614,331.22300,508,546.72545,589,123.77
归属于母公司股东权益合计3,400,982,718.453,428,778,232.713,387,633,001.373,335,223,635.33
股东权益合计3,403,624,673.473,430,490,749.233,403,302,403.923,353,682,716.05
负债和股东权益合计3,604,263,315.163,701,105,080.453,703,810,950.643,899,271,839.82
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计437,535,320.83343,756,387.17163,459,229.153,395,105,604.4
经营活动现金流出小计788,880,801.82543,275,673.17406,243,576.752,416,352,436.47
经营活动产生的现金流量净额-351,345,480.99-199,519,286-242,784,347.6978,753,167.93
投资活动现金流入小计966,149,915.82815,601,272.57607,831,021.952,095,171,566.38
投资活动现金流出小计937,578,624.37803,516,351.36561,508,312.583,225,223,633.36
投资活动产生的现金流量净额28,571,291.4512,084,921.2146,322,709.37-1,130,052,066.98
筹资活动现金流入小计7,140,351.117,140,351.11-8,320,000
筹资活动现金流出小计16,444,443.6516,956,935.066,483,618.22493,307,022.35
筹资活动产生的现金流量净额-9,304,092.54-9,816,583.95-6,483,618.22-484,987,022.35
汇率变动对现金及现金等价物的影响2,965,935.75-366,537.32-1,285,097.965,198,170.06
现金及现金等价物净增加额-329,112,346.33-197,617,486.06-204,230,354.41-631,087,751.34
期末现金及现金等价物余额194,102,372.57325,597,232.84318,984,364.49523,214,718.9
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
林长青2168.2523.500.00
周锌780.668.460.00
青岛同程热景企业管理咨询合伙企业(有限合伙)461.305.00-92.26
杭州迪通创健股权投资基金管理有限公司-浙江大健康产业股权投资基金(有限合伙)323.733.51-36.79
北京热景生物技术股份有限公司回购专用证券账户286.153.100.00
陈建辉66.800.7217.60
香港中央结算有限公司56.210.6156.21
安丘市云集投资基金中心(有限合伙)47.780.520.00
俞海峰36.480.40-0.52
邵魁30.950.3430.95
  主力控盘
  公司简介
热景生物 所属地域: 北京市 涉及概念: 重组蛋白,抗原检测,猴痘概念,肝炎概念,新冠治疗,新冠检测,流感,医疗器械概念,食品安全,融资融券
主营业务: 技术开发、技术转让、技术服务、技术咨询;货物进出口;技术进出口;代理进出口;租赁、维修医疗器械;销售医疗器械(Ⅱ类);软件开发;健康咨询(须经审批的诊疗活动除外);生产第二类、第三类医疗器械;销售食品;销售第三类医疗器械。(企业依法自主选择经营项目,开展经营活动;生产第二类、第三类医疗器械、销售食品、销售第三类医疗器械以及依法须经批准的项目,经相关部门批准后依批准的内容开展经营活动;不得从事本市产业政策禁止和限制类项目的经营活动。)
上市日期: 2019-09-30 每股净资产: 36.86元 每股收益: 0.61元 净利润: 0.54亿元 净利润增长率: -95.06%
营业收入: 4.07亿元 每股现金流: -3.81元 每股公积金: 4.80元 每股未分配利润: 32.37元 总股本: 0.92亿 流通股: 0.92亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心